Skip to main content
françaisFR
European Commission logo print header

A Multi-Stage Malaria Vaccine

Objectif

A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.
Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life-cycle allow testing of a multi-stage multi-component vaccine for the first time, with strong chances of success. These advances are i) the availability of a new vectored prime-boost vaccination regime based on the ReiThera Srl's chimpanzee adenovirus technology that has been found to induce exceptionally potent CD8+ T cell responses and high titre antibodies against multiple malaria antigens; ii) the development of an improved version of the leading partially protective RTS,S sporozoite vaccine candidate, termed R21, that lacks the excess of HBsAg in RTS,S; iii) the identification, using a vector technology screen, of the blood-stage antigen RH5 as the first antigen to induce potent strain-transcending neutralisation of blood-stage parasites in in vitro growth inhibition assays; and iv) the demonstration that vector-induced antibodies against two mosquito-stage antigens can induce 100% transmission blocking against field isolates of P. falciparum in Africa.
We will undertake four phase I / II clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components individually, and then together, using state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2012-INNOVATION-1
Voir d’autres projets de cet appel

Régime de financement

CP-FP - Small or medium-scale focused research project

Coordinateur

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Contribution de l’UE
€ 4 724 875,50
Adresse
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Royaume-Uni

Voir sur la carte
Région
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Participants (5)

Partager cette page

Télécharger

Dernière mise à jour: 30 Mars 2016

Mon livret

Permalink: https://cordis.europa.eu/project/id/305282/fr

European Union, 2024